VIPRa peptides

VIPRa (Viral Inhibitor Peptide-based Radiopharmaceuticals) peptides are a class of theranostic agents developed for the targeted imaging and treatment of SARS-CoV-2 infections. Developed by a consortium led by the University of Queensland and ANSTO, these peptides are engineered to bind with high affinity to the receptor-binding domain (RBD) of the SARS-CoV-2 spike protein. By occupying the RBD, the peptides competitively inhibit the interaction between the virus and the host cell's ACE2 receptor, effectively blocking viral entry. The platform utilizes radiolabeling with isotopes such as Gallium-68 for PET imaging or Lutetium-177 for targeted radiotherapy, allowing for the simultaneous detection of viral distribution and the delivery of therapeutic radiation or antiviral effects. This approach was specifically designed to address the need for rapid diagnostic and therapeutic responses during the COVID-19 pandemic.

Other names

Viral Inhibitor Peptide-based Radiopharmaceuticals